Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Dermatol Surg. 2010 May;36(5):630-5. doi: 10.1111/j.1524-4725.2010.01517.x. Epub 2010 Apr 2.
To assess the clinical efficacy and safety of potassium titanyl phosphate (KTP) laser treatment and electrocoagulation (EC) for the treatment of spider nevi (SN).
A randomized single-blind intrapatient comparison study was performed. A blinded observer and patients reported the clinical treatment outcome and pain on a visual analogue scale (0-10). Side effects were noted if present.
Mean physician-rated clinical efficacy scores+/-standard error of the mean were 7.7+/-0.7 for KTP laser and 6.2+/-0.9 for EC treatment (p=.05). Patient-rated mean clinical efficacy of KTP laser was 8.3+/-0.6 and of EC was 7.3+/-0.7 (p=.09). Stratification for potential confounding bias, such as location of SN, central bulging vein, and diameter (p=.25) of the treated SN did not reveal any statistically significant differences between the treatments. Treatment with KTP or EC did not result in scarring or pigmentary changes. Pain was reported for KTP treatment (3.1+/-0.4) and EC (6.4+/-0.7) (p<.05).
Clinical efficacy of KTP laser and EC for SN is comparable, although there is a tendency toward an advantage in favor of the KTP laser. KTP laser treatment was less painful.
评估钛钾磷酸盐(KTP)激光治疗和电凝(EC)治疗蜘蛛痣(SN)的临床疗效和安全性。
进行了一项随机、单盲、自身对照研究。由一名盲法观察者和患者使用视觉模拟评分(0-10)报告临床治疗效果和疼痛。如果出现副作用则进行记录。
平均医生评估的临床疗效评分+/-标准误差分别为 KTP 激光治疗组为 7.7+/-0.7,EC 治疗组为 6.2+/-0.9(p=.05)。KTP 激光治疗的患者平均临床疗效评分为 8.3+/-0.6,EC 治疗的评分为 7.3+/-0.7(p=.09)。对潜在混杂偏差(如 SN 的位置、中央隆起静脉和治疗 SN 的直径(p=.25))进行分层,治疗之间没有显示出任何统计学上的显著差异。KTP 或 EC 治疗均未导致瘢痕或色素变化。KTP 治疗(3.1+/-0.4)和 EC 治疗(6.4+/-0.7)均有疼痛报告(p<.05)。
尽管 KTP 激光治疗有倾向于优势,但 KTP 激光和 EC 治疗 SN 的临床疗效相当。KTP 激光治疗的疼痛程度较轻。